5% of patients treated with the higher dose of rofecoxib
showed improvement, compared with 55.
In another study published in Annals of Internal Medicine, the COX-2 inhibitor rofecoxib
was compared to indomethacin, confirming that these drugs reduce kidney function.
The relative risk for MI doubled with rofecoxib
or lumiracoxib, was 35% higher with celecoxib, and was 61% higher with ibuprofen, compared with placebo.
Results showed that the relative risk (RR) of developing a confirmed cardiovascular event with rofecoxib
compared with naproxen was 2.
These data led to the withdrawal of rofecoxib
from the world market in September 2004.
Another Cochrane review (5) (26 randomized controlled trials) found that rofecoxib
(Vioxx) was more effective than placebo (NNT=5), and equally effective with other NSAIDs in the management of osteoarthritis.
Patients were asked about their medication use through phone interviews (although only half responded), and were divided into nonusers of NSAIDs, rofecoxib
users, celecoxib users, and nonselective NSAID users.
US Drug Safety chief Dr David Graham said: 'Between 88,000140,000 excess cases of serious coronary heart disease probably occurred in the US over the market life of rofecoxib
gave a daily pill of the drug rofecoxib
(Vioxx), a Merck-patented NSAID prescribed for arthritis, or an inert pill to 692 people over age 50 who had early Alzheimer's disease.
This is the first clinical trial to prospectively test rofecoxib
(Vioxx[R]), a selective cyclooxygenase-2 (COX-2) inhibitor, and naproxen (Naprosyn[R]), a nonselective NSAID, in patients with AD.
47, supplement 1) focusing on the adverse cardiovascular effects of rofecoxib
In an analysis controlling for age, gender, comorbidities, and concomitant medications, people treated with ibuprofen, diclofenac, rofecoxib
, or celecoxib had a significantly increased risk for fatal or nonfatal stroke.
and valdecoxib are no longer on pharmacy shelves, and new studies raise questions about the cardiac safety of some remaining painkillers.
That goes up to 24 per cent for ibuprofen, 32 per cent for rofecoxib
and 55 per cent for diclofenac.
market, with nearly unanimous support for celecoxib but far narrower votes for rofecoxib
and valdecoxib, reflecting the strength of the data on the cardiovascular risks seen with those two drugs.